{"id":70731,"date":"2026-07-27T21:20:35","date_gmt":"2026-07-27T13:20:35","guid":{"rendered":"https:\/\/flcube.com\/?p=70731"},"modified":"2026-07-27T21:20:39","modified_gmt":"2026-07-27T13:20:39","slug":"roches-susvimo-receives-chmp-recommendation-for-neovascular-amd-with-contivue-implant-delivery-system","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=70731","title":{"rendered":"Roche&#8217;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Roche Holding AG<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/ROP:SWX\">SWX: ROP<\/a>; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/RHHBY:OTCMKTS\">OTCMKTS: RHHBY<\/a>) announced that the <strong>European Medicines Agency&#8217;s Committee for Medicinal Products for Human Use (CHMP)<\/strong> has recommended approval of <strong>Susvimo (ranibizumab injection) 100 mg\/mL<\/strong> for the treatment of <strong>neovascular age-related macular degeneration (nAMD)<\/strong>. Susvimo is designed for continuous release into the vitreous using the <strong>Contivue implant<\/strong>, with a final European Commission decision expected in the near future.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Company<\/strong><\/td><td>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY)<\/td><\/tr><tr><td><strong>Product<\/strong><\/td><td>Susvimo (ranibizumab injection) 100 mg\/mL with Contivue implant<\/td><\/tr><tr><td><strong>Indication<\/strong><\/td><td>Neovascular age-related macular degeneration (nAMD)<\/td><\/tr><tr><td><strong>Regulatory Body<\/strong><\/td><td>EMA\/CHMP (European Union)<\/td><\/tr><tr><td><strong>Recommendation Type<\/strong><\/td><td>Positive opinion recommending marketing authorization<\/td><\/tr><tr><td><strong>Delivery System<\/strong><\/td><td>Port Delivery Platform (Contivue implant)<\/td><\/tr><tr><td><strong>CE Mark Status<\/strong><\/td><td>Contivue implant granted CE mark in 2025<\/td><\/tr><tr><td><strong>Next Steps<\/strong><\/td><td>European Commission final decision expected shortly<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-product-profile-amp-innovation\" class=\"wp-block-heading\">Product Profile &amp; Innovation<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Therapeutic Class:<\/strong> Anti-vascular endothelial growth factor (anti-VEGF) agent<\/li>\n\n\n\n<li><strong>Active Ingredient:<\/strong> Ranibizumab (same molecule as Lucentis)<\/li>\n\n\n\n<li><strong>Delivery Innovation:<\/strong> Continuous drug delivery via surgically implanted Contivue reservoir<\/li>\n\n\n\n<li><strong>Dosing Frequency:<\/strong> Two refills per year versus monthly intravitreal injections<\/li>\n\n\n\n<li><strong>Patient Benefit:<\/strong> Reduces clinic visit frequency while maintaining equivalent visual outcomes<\/li>\n\n\n\n<li><strong>Technical Specification:<\/strong> Contivue implant specifically engineered for use with Susvimo formulation<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-evidence-pivotal-trial-data\" class=\"wp-block-heading\">Clinical Evidence \u2013 Pivotal Trial Data<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Endpoint<\/th><th>Result (Susvimo)<\/th><th>Comparator (Monthly IVT Ranibizumab)<\/th><th>Equivalence<\/th><\/tr><\/thead><tbody><tr><td><strong>Visual Acuity Outcomes<\/strong><\/td><td>Equivalent maintenance<\/td><td>Standard of care<\/td><td><strong>Non-inferior<\/strong><\/td><\/tr><tr><td><strong>Supplemental Treatment Need<\/strong><\/td><td>5% required additional anti-VEGF<\/td><td>N\/A<\/td><td><strong>95% treatment independence<\/strong><\/td><\/tr><tr><td><strong>Long-term Vision Maintenance<\/strong><\/td><td>Up to 7 years (Portal study)<\/td><td>Limited long-term data<\/td><td><strong>Sustained efficacy<\/strong><\/td><\/tr><tr><td><strong>Safety Profile<\/strong><\/td><td>Generally well tolerated over long term<\/td><td>Known ranibizumab safety profile<\/td><td><strong>Consistent with class<\/strong><\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p class=\"wp-block-paragraph\">The recommendation is based on data from three clinical studies:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Archway:<\/strong> Pivotal Phase III study demonstrating equivalence to monthly ranibizumab<\/li>\n\n\n\n<li><strong>LADDER:<\/strong> Phase II supportive study<\/li>\n\n\n\n<li><strong>Portal:<\/strong> Open-label long-term extension study showing vision maintenance up to seven years<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-strategic-outlook\" class=\"wp-block-heading\">Market Impact &amp; Strategic Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>nAMD Market Size:<\/strong> Affects approximately 1.5 million patients in EU5 countries with annual treatment costs exceeding \u20ac3 billion<\/li>\n\n\n\n<li><strong>Treatment Burden:<\/strong> Current standard requires monthly or bimonthly intravitreal injections, creating significant patient and healthcare system burden<\/li>\n\n\n\n<li><strong>Competitive Positioning:<\/strong> First continuous-delivery anti-VEGF therapy approved in Europe, offering differentiated dosing schedule<\/li>\n\n\n\n<li><strong>Revenue Potential:<\/strong> Analysts project peak annual sales of \u20ac450-600 million if approved, capturing 15-20% of the nAMD market<\/li>\n\n\n\n<li><strong>Healthcare Economics:<\/strong> Potential to reduce clinic visits by 80%, generating significant healthcare system savings through reduced administration costs<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> Strengthens Roche&#8217;s ophthalmology portfolio alongside existing Lucentis franchise and complements Genentech&#8217;s US commercialization efforts<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward-looking statements regarding regulatory timelines, clinical outcomes, and commercial expectations for Susvimo. Actual results may differ due to risks including final approval conditions, market adoption, competitive dynamics, reimbursement decisions, and surgical implant adoption rates among retinal specialists.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency&#8217;s Committee for&#8230;<\/p>\n","protected":false},"author":1,"featured_media":70733,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11],"tags":[38,44,940,163,939],"class_list":["post-70731","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","tag-market-approval-filings","tag-ophthalmology","tag-otcmkts-rhhby","tag-roche","tag-swx-rop"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.1) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Roche&#039;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency&#039;s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=70731\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Roche&#039;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System\" \/>\n<meta property=\"og:description\" content=\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency&#039;s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=70731\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-07-27T13:20:35+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-07-27T13:20:39+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Roche&#8217;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System\",\"datePublished\":\"2026-07-27T13:20:35+00:00\",\"dateModified\":\"2026-07-27T13:20:39+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731\"},\"wordCount\":451,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2703.webp\",\"keywords\":[\"Market approval filings\",\"Ophthalmology\",\"OTCMKTS: RHHBY\",\"Roche\",\"SWX: ROP\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70731#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=70731\",\"name\":\"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2703.webp\",\"datePublished\":\"2026-07-27T13:20:35+00:00\",\"dateModified\":\"2026-07-27T13:20:39+00:00\",\"description\":\"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\\\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=70731\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2703.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/07\\\/2703.webp\",\"width\":1080,\"height\":608,\"caption\":\"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=70731#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Roche&#8217;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System - Insight, China&#039;s Pharmaceutical Industry","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=70731","og_locale":"en_US","og_type":"article","og_title":"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System","og_description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.","og_url":"https:\/\/flcube.com\/?p=70731","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-07-27T13:20:35+00:00","article_modified_time":"2026-07-27T13:20:39+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=70731#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=70731"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Roche&#8217;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System","datePublished":"2026-07-27T13:20:35+00:00","dateModified":"2026-07-27T13:20:39+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=70731"},"wordCount":451,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=70731#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","keywords":["Market approval filings","Ophthalmology","OTCMKTS: RHHBY","Roche","SWX: ROP"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=70731#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=70731","url":"https:\/\/flcube.com\/?p=70731","name":"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=70731#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=70731#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","datePublished":"2026-07-27T13:20:35+00:00","dateModified":"2026-07-27T13:20:39+00:00","description":"Roche Holding AG (SWX: ROP; OTCMKTS: RHHBY) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Susvimo (ranibizumab injection) 100 mg\/mL for the treatment of neovascular age-related macular degeneration (nAMD). Susvimo is designed for continuous release into the vitreous using the Contivue implant, with a final European Commission decision expected in the near future.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=70731#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=70731"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=70731#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","width":1080,"height":608,"caption":"Roche's Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=70731#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Roche&#8217;s Susvimo Receives CHMP Recommendation for Neovascular AMD with Contivue Implant Delivery System"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/07\/2703.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70731","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=70731"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70731\/revisions"}],"predecessor-version":[{"id":70734,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/70731\/revisions\/70734"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/70733"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=70731"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=70731"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=70731"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}